Interactions of IgG1 CH2 and CH3 Domains with FcRn.
Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small-size and other unique properties. However, when compared to full-size antibodies, most of the current antibody fragments of VH or VL display greatly reduced half-lives. A promising approach to overcome this problem is through the development of novel antibody fragments based on IgG Fc region, which contributes to the long half-life of IgG through its unique pH-dependent association with the neonatal Fc receptor (FcRn). The IgG Fc region comprises two CH2 and two CH3 domains. In this report, we present a comparative study of the FcRn binding capability of the CH2 and CH3 domains. The stability and aggregation resistance of these domains were also investigated and compared. We found that monomeric CH2 and CH3 domains exhibited the pH-dependent FcRn binding while the dimeric forms of CH2 and CH3 domains did not. Although all of these domains had high serum stability, they had aggregation tendencies as measured by dynamic light scattering. By providing a better understanding of the structure-activity relationship of the Fc fragment, these results guide further approaches to generate novel Fc-based small-size antibody fragments that possess pH-dependent FcRn binding capability, desired in vivo half-lives, and other favorable biophysical properties for their druggability.
Protein Interactions Group, Cancer and Inflammation Program, National Cancer Institute, National Institutes of Health , Frederick, MD , USA.
Tianlei
T
Ying
Protein Interactions Group, Cancer and Inflammation Program, National Cancer Institute, National Institutes of Health , Frederick, MD , USA.
Tina W
TW
Ju
Protein Interactions Group, Cancer and Inflammation Program, National Cancer Institute, National Institutes of Health , Frederick, MD , USA ; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research , Frederick, MD , USA.
Yanping
Y
Wang
Protein Interactions Group, Cancer and Inflammation Program, National Cancer Institute, National Institutes of Health , Frederick, MD , USA ; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research , Frederick, MD , USA.
Ponraj
P
Prabakaran
Protein Interactions Group, Cancer and Inflammation Program, National Cancer Institute, National Institutes of Health , Frederick, MD , USA.
Dimiter S
DS
Dimitrov
CH2 domain; CH3 domain; FcRn; antibody fragments; small-size